BioNTech SE (BNTX) is a top high-growth international stock to buy, with a Buy rating and $143.00 price target maintained by BMO Capital analyst Evan Seigerman. The optimistic rating is due to the anticipation of a stable COVID-19 vaccine business and an emerging pipeline driving potential share price appreciation. The German biotech company specializes in mRNA therapeutics and vaccines for serious diseases. While BNTX shows investment potential, there are AI stocks with greater upside and less downside risk.

Read more at Yahoo Finance: BMO Capital Maintains a Buy on BioNTech SE (BNTX)